No Data
[Brokerage Focus] CITIC SEC: The integration of the Traditional Chinese Medicine Industry is accelerating, and the leading players are expected to strengthen their position.
Jinwu Financial News | CITIC SEC states that the price of Traditional Chinese Medicine materials has entered a downward channel, and improvements in industrial costs are worth anticipating. Starting in January 2025, Traditional Chinese Medicine companies will successively complete inventory clearance through channels, and numerous e-commerce activities will occur during the Spring Festival, with strong purchasing power among Consumers. The e-commerce platforms' sales of Pharmaceutical products generally achieve high year-on-year growth rates. Benefiting from policy support and the accelerated aging of the population, the bank expects that overall demand for Traditional Chinese Medicine will continue to improve in the future, with industry consolidation accelerating, and leading companies are likely to become stronger.
Hong Kong stock Concept tracking | Promoting the value assessment and allocation of Traditional Chinese Medicine Pharmaceuticals, Institutions are Bullish on the recovery of Traditional Chinese Medicine revenue (with attached Concept stocks)
The General Office of the State Council issued the "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry."
Hong Kong stock movements | Some Traditional Chinese Medicine concept stocks opened higher, with TRAD CHI MED (00570) opening over 8% higher. The State Council has issued a document to promote the high-quality development of Traditional Chinese Medicine.
Some Traditional Chinese Medicine concept stocks opened higher. As of the time of writing, TRAD CHI MED (00570) rose by 8.06%, trading at 2.28 HKD; TONGRENTANGCM (03613) increased by 4.64%, trading at 9.02 HKD; and Gushengtang (02273) rose by 3.45%, trading at 41.95 HKD.
TONGRENTANGCM (03613.HK) will hold a Board of Directors meeting on March 28 to approve the annual performance.
Gelonghui reported on March 13 that TONGRENTANGCM (03613.HK) announced that the company will hold a Board of Directors meeting on March 28, 2025, to consider and approve the group's annual performance for the year ending December 31, 2024, and its publication, as well as to consider the distribution of a final dividend (if any).
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
CLSA PREMIUM received a discount of approximately 33.57% from Beijing Tongrentang (Cayman) Limited for the full purchase offer.
CLSA PREMIUM (06877) and the offeror Beijing Tongrentang (Cayman) Ltd jointly announced that on February 18, 2025, the offeror completed the acquisition of approximately 0.813 billion shares from CITIC SEC International Ltd, accounting for 40% of the company's total issued share capital as of the date of this joint announcement, for a total consideration of 97.994 million Hong Kong dollars (equivalent to about 0.1205 Hong Kong dollars per share sold). Following the completion and as of the date of this joint announcement, the offeror and its concert parties (including the seller) own about 1.2 billion shares (approximately 59.03% of the company's total issued share capital).
